Shares of Accelerate Diagnostics Inc. (NASDAQ:AXDX) rose 2.8% on Friday . The company traded as high as $20.64 and last traded at $20.44, with a volume of 101,988 shares trading hands. The stock had previously closed at $19.88.

AXDX has been the subject of a number of analyst reports. BTIG Research restated a “buy” rating and set a $26.00 price objective on shares of Accelerate Diagnostics in a research note on Monday, April 11th. Zacks Investment Research lowered shares of Accelerate Diagnostics from a “hold” rating to a “sell” rating in a research note on Wednesday, July 13th. Finally, Piper Jaffray Cos. restated an “overweight” rating and set a $25.00 price objective on shares of Accelerate Diagnostics in a research note on Monday, May 16th. One research analyst has rated the stock with a sell rating and four have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $22.67.

The stock’s 50 day moving average price is $16.28 and its 200 day moving average price is $14.19. The company’s market cap is $1.05 billion.

In other Accelerate Diagnostics news, Director Jack W. Schuler acquired 10,000 shares of the stock in a transaction that occurred on Tuesday, May 17th. The stock was bought at an average cost of $11.45 per share, with a total value of $114,500.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Jack W. Schuler acquired 20,000 shares of the stock in a transaction that occurred on Friday, May 13th. The stock was acquired at an average cost of $12.45 per share, with a total value of $249,000.00. The disclosure for this purchase can be found here.

An institutional investor recently raised its position in Accelerate Diagnostics stock. Neuberger Berman Group LLC boosted its position in Accelerate Diagnostics Inc. (NASDAQ:AXDX) by 124.0% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 48,500 shares of the company’s stock after buying an additional 26,850 shares during the period. Neuberger Berman Group LLC owned about 0.11% of Accelerate Diagnostics worth $1,042,000 at the end of the most recent reporting period.

Accelerate Diagnostics, Inc is an in vitro diagnostics company engaged in providing solutions that improve patient outcomes and lower healthcare costs through the diagnosis of serious infections. The Company’s technology platform is built to address these challenges by delivering testing of infectious pathogens in various patient sample types.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.